Correlation between PD-L1 and Ki-67 Expression at various T-stage Clear Cell Renal Cell Carcinomas

Q3 Pharmacology, Toxicology and Pharmaceutics Research Journal of Pharmacy and Technology Pub Date : 2024-01-19 DOI:10.52711/0974-360x.2024.00017
Anny Setijo Rahaju, A. Rahniayu, Etty Hary Kusumastuti, Priangga Adi Wiratama, Pamela Kusumadewi P. Thaib, Mimi Takaria
{"title":"Correlation between PD-L1 and Ki-67 Expression at various T-stage Clear Cell Renal Cell Carcinomas","authors":"Anny Setijo Rahaju, A. Rahniayu, Etty Hary Kusumastuti, Priangga Adi Wiratama, Pamela Kusumadewi P. Thaib, Mimi Takaria","doi":"10.52711/0974-360x.2024.00017","DOIUrl":null,"url":null,"abstract":"Renal cell carcinoma (RCC) is a malignant neoplasm originating from renal epithelium, with the clear cell renal cell carcinoma (ccRCC)being the most common type (80%) and the most common cause of death among other types of kidney cancer. Pathological stage is an important parameter that affects ccRCC survival, followed by nuclear grade. Pathological staging of RCC according to the AJCC (American Joint Committee on Cancer) TNM system 8th edition is based on local extension of the main tumor (T), involvement of lymph node (N), and metastasis (M). Ki-67 is a marker of proliferation used to assess tumor grade. High Ki-67 correlates with poor prognosis, advanced clinical and pathological features, thus Ki-67 can be used as a biomarker in the management of RCC.Ki-67 is routinely used to see the proliferation index in various cases of malignancy, but not in kidney malignancy. Programmed death ligand 1 (PD-L1) acts as a negative regulator of T cell-mediated anti-tumor immune responses. PD-L1 is expressed on T cells, B cells, macrophages, dendritic cells, endothelial cells and in various tumor cells including ccRCC. This study aims to determine the correlation between the expression of PD-L1 and Ki-67 in various T-stage clear cell renal cell carcinomas. Material and Method: This was an observational analytical study with cross-sectional approach toward 52 cases of ccRCC whose diagnosis was made histopathologically at the Anatomical Pathology Installation of Dr. Soetomo General Academic Hospital Surabaya from January 2014 to December 2020. Immunohistochemical stainingwas carried out using Ki-67 and PD-L1 antibodies, followed by an assessment using a scoring system. T-stage data were obtained from the patients’ medical recordswhich were then analyzed statistically with the Spearman test. Result: The study included 52 cases of ccRCC obtained from nephrectomy specimens at RSUD dr. Soetomo between 2014–2020. The age distribution of the subjects was 29–69 years and the mean and median age was 53 years. The ratio of male patients compared to female patients was 2.5:1. The majority was stage T2 (50%). Statistical test results showed no correlation between the expression of PD-L1 and Ki-67 in various T-stage clear cell renal cell carcinomas (p=0.965 and p=0.680). Conclusion: This study showed no correlation between the expression of PD-L1 and Ki-67 in various T-stage clear cell renal cell carcinomas. Nonetheless PD-L1 can be considered as an important biomarker with a poorer prognosis and aggressive clinicopathological findings in patients with RCC.","PeriodicalId":21141,"journal":{"name":"Research Journal of Pharmacy and Technology","volume":"5 3-4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research Journal of Pharmacy and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52711/0974-360x.2024.00017","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Renal cell carcinoma (RCC) is a malignant neoplasm originating from renal epithelium, with the clear cell renal cell carcinoma (ccRCC)being the most common type (80%) and the most common cause of death among other types of kidney cancer. Pathological stage is an important parameter that affects ccRCC survival, followed by nuclear grade. Pathological staging of RCC according to the AJCC (American Joint Committee on Cancer) TNM system 8th edition is based on local extension of the main tumor (T), involvement of lymph node (N), and metastasis (M). Ki-67 is a marker of proliferation used to assess tumor grade. High Ki-67 correlates with poor prognosis, advanced clinical and pathological features, thus Ki-67 can be used as a biomarker in the management of RCC.Ki-67 is routinely used to see the proliferation index in various cases of malignancy, but not in kidney malignancy. Programmed death ligand 1 (PD-L1) acts as a negative regulator of T cell-mediated anti-tumor immune responses. PD-L1 is expressed on T cells, B cells, macrophages, dendritic cells, endothelial cells and in various tumor cells including ccRCC. This study aims to determine the correlation between the expression of PD-L1 and Ki-67 in various T-stage clear cell renal cell carcinomas. Material and Method: This was an observational analytical study with cross-sectional approach toward 52 cases of ccRCC whose diagnosis was made histopathologically at the Anatomical Pathology Installation of Dr. Soetomo General Academic Hospital Surabaya from January 2014 to December 2020. Immunohistochemical stainingwas carried out using Ki-67 and PD-L1 antibodies, followed by an assessment using a scoring system. T-stage data were obtained from the patients’ medical recordswhich were then analyzed statistically with the Spearman test. Result: The study included 52 cases of ccRCC obtained from nephrectomy specimens at RSUD dr. Soetomo between 2014–2020. The age distribution of the subjects was 29–69 years and the mean and median age was 53 years. The ratio of male patients compared to female patients was 2.5:1. The majority was stage T2 (50%). Statistical test results showed no correlation between the expression of PD-L1 and Ki-67 in various T-stage clear cell renal cell carcinomas (p=0.965 and p=0.680). Conclusion: This study showed no correlation between the expression of PD-L1 and Ki-67 in various T-stage clear cell renal cell carcinomas. Nonetheless PD-L1 can be considered as an important biomarker with a poorer prognosis and aggressive clinicopathological findings in patients with RCC.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
不同 T 期透明细胞肾细胞癌中 PD-L1 和 Ki-67 表达的相关性
肾细胞癌(RCC)是一种起源于肾上皮的恶性肿瘤,其中透明细胞肾细胞癌(ccRCC)是最常见的类型(80%),也是其他类型肾癌中最常见的死亡原因。病理分期是影响ccRCC存活率的重要参数,其次是核分级。根据 AJCC(美国癌症联合委员会)TNM 系统第 8 版,RCC 的病理分期基于主瘤局部扩展(T)、淋巴结受累(N)和转移(M)。Ki-67 是一种用于评估肿瘤等级的增殖标记物。高Ki-67与预后不良、晚期临床和病理特征相关,因此Ki-67可作为治疗RCC的生物标志物。Ki-67可常规用于观察各种恶性肿瘤的增殖指数,但不适用于肾脏恶性肿瘤。程序性死亡配体 1(PD-L1)是 T 细胞介导的抗肿瘤免疫反应的负调控因子。PD-L1 在 T 细胞、B 细胞、巨噬细胞、树突状细胞、内皮细胞以及包括 ccRCC 在内的各种肿瘤细胞中均有表达。本研究旨在确定各种T期透明细胞肾细胞癌中PD-L1和Ki-67表达之间的相关性。材料与方法:这是一项横断面观察分析研究,研究对象是泗水苏托莫博士综合学术医院解剖病理室从2014年1月至2020年12月对52例经组织病理学确诊的ccRCC病例。使用 Ki-67 和 PD-L1 抗体进行免疫组化染色,然后使用评分系统进行评估。从患者的病历中获取T期数据,然后用斯皮尔曼检验进行统计分析。结果研究包括 2014-2020 年间在 RSUD Dr. Soetomo 肾切除标本中获得的 52 例 ccRCC。研究对象的年龄分布为 29-69 岁,平均年龄和中位年龄均为 53 岁。男性患者与女性患者的比例为 2.5:1。大多数患者为 T2 期(50%)。统计检测结果显示,在不同的T期透明细胞肾细胞癌中,PD-L1和Ki-67的表达没有相关性(P=0.965和P=0.680)。结论本研究显示,PD-L1和Ki-67的表达在不同T期透明细胞肾细胞癌中没有相关性。尽管如此,PD-L1仍可被视为RCC患者预后较差和临床病理结果具有侵袭性的重要生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Research Journal of Pharmacy and Technology
Research Journal of Pharmacy and Technology Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
CiteScore
1.40
自引率
0.00%
发文量
0
期刊介绍: Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal, devoted to pharmaceutical sciences. The aim of RJPT is to increase the impact of pharmaceutical research both in academia and industry, with strong emphasis on quality and originality. RJPT publishes Original Research Articles, Short Communications, Review Articles in all areas of pharmaceutical sciences from the discovery of a drug up to clinical evaluation. Topics covered are: Pharmaceutics and Pharmacokinetics; Pharmaceutical chemistry including medicinal and analytical chemistry; Pharmacognosy including herbal products standardization and Phytochemistry; Pharmacology: Allied sciences including drug regulatory affairs, Pharmaceutical Marketing, Pharmaceutical Microbiology, Pharmaceutical biochemistry, Pharmaceutical Education and Hospital Pharmacy.
期刊最新文献
Investigations of Biological activities and Characterisation of Phytochemical constituents of Pulicaria laciniata extracts, an Endemic plant growing in south of Algeria Comparative Teratogenic and Skin whitening effect of Herbal extract Glycyrrhiza glabra and Citrus sineus on Zebrafish (Danio rerio) In vitro Evaluation of Anticancer Activity of Karanthai Legium (Kl) – A Siddha Medicine for Cervical Carcinoma against Hela Cell Line By MTT Assay In silico ADME/T Prediction of Steroidal Chalcone derivatives using Swiss ADME and OSIRIS explorer Clinico-hematological Profile and Cytogenetics in Myelodysplastic Syndrome - A Tertiary Care Experience
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1